



## DATA SHEET

PRODUCT NAME Anti-SARS-CoV-2 RBD cross-reactive monoclonal antibody (clone 175)

REPOSITORY REFERENCE 101119-B

LOT NUMBER OFD

DESCRIPTION A cross-reactive RBD/ spike mouse monoclonal antibody to SARS-CoV-2.

The plasmid expressing the monoclonal antibody was sequenced and transfected in CHO cells for 10-liter scale production. Accelerated stability studies to evaluate the effect of 3 freeze-thaw cycles and exposure to 40°C for 3 days were conducted on the purified antibody. No differences in antibody stability were observed by size exclusion ultraperformance liquid chromatography and capillary electrophoresis SDS under the accelerated conditions studied.


Antibody clone 175 was found to recognise all SARS-CoV-2 RBD and spike antigens tested.

### SPECIFICITY


Reactivity	Variant	Protein	Expression
+	Wuhan*	RBD	Yeast
+	Delta*	RBD	Yeast
+	Omicron BA.4/5*	RBD	Yeast
+	Beta	RBD	HEK293
+	Delta	RBD	HEK293
+	Gamma*	RBD	HEK293
+	Omicron BA.1*	RBD	HEK293
+	Omicron BA.2*	RBD	HEK293
+	Omicron BA.4*	RBD	HEK293
+	Wuhan*	Spike	Insect
+	Delta*	Spike	Insect
+	Omicron BA.1*	Spike	Insect
+	Wuhan*	Spike	NDV-spike

\* Antigens are shown in sample ELISA specificity in Figure 1.


**Table 1. Specificity of antibody clone 175 binding to antigen variants**



**Figure 1. Antibody clone 175 RBD cross-reactivity.** Dilutions of the purified clone 175 CHO antibodies were used to detect immobilized RBD antigens on ELISA plates (\*Antigens shown in Table 1).



**Figure 2. Antibody clone 175 spike cross-reactivity.** Dilutions of the purified clone 175 CHO antibodies were used to detect immobilized spike antigens on ELISA plates (\*Antigens shown in Table 1).



**Figure 3. Western blot using antibody clone 175.**

PROVIDED 1mL (5.06 mg/mL)

STORAGE -80°C

DEPOSITOR Jessica White, PATH

ADDITIONAL INFORMATION **Request for 5mg aliquot has to be approved by PATH. Alternatively, 200µg aliquots are available: 101119-A.**

**ACKNOWLEDGEMENTS**

Publications should acknowledge the contributor and the Centre for AIDS Reagents (CFAR). Acknowledgments should read: “The *Name of Reagent (Repository Number)* was obtained from the Centre for AIDS Reagents, NIBSC, UK, thanks to Jessica White, PATH.”



MATERIAL SAFETY SHEET

<b>Physical properties (at room temperature)</b>			
Physical appearance	Clear, liquid		
Fire hazard	None		
<b>Chemical properties</b>			
Stable	Yes	Corrosive:	No
Hygroscopic	No	Oxidising:	No
Flammable	No	Irritant:	No
Other: This product is a genetically modified material; it is the responsibility of the end user to seek local biosafety approval for the storage and handling of the material in their workplace			
Handling: CAUTION - This preparation is not for administration to humans or animals in the human food chain. This preparation is hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective clothing, gloves, and avoiding the generation of aerosols.			
<b>Toxicological properties</b>			
Effects of inhalation:	Not established, avoid inhalation		
Effects of ingestion:	Not established, avoid ingestion		
Effects of skin absorption:	Not established, avoid contact with skin		
<b>Suggested First Aid</b>			
Inhalation	Seek medical advice		
Ingestion	Seek medical advice		
Contact with eyes	Wash with copious amounts of water. Seek medical advice.		
Contact with skin	Wash thoroughly with water.		
<b>Action on Spillage and Method of Disposal</b>			
Spillage of vial contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with a virucidal agent followed by water.			